Breaking News, Trials & Filings

Sanofi’s Rezurock Approved in EU for Treatment of Chronic Graft-Versus-Host Disease

GVHD is a life-threatening complication that can occur following a stem cell transplant.

Author Image

By: Patrick Lavery

Content Marketing Editor

Sanofi has received conditional marketing authorization from the European Commission (EC) for Rezurock (belumosudil), to treat chronic graft-versus-host disease (GVHD). The approval applies to adult patients as well as children aged 12 and older. Patients must have a minimum body weight of 40 kg (88 lbs.). What is Graft-Versus-Host? GVHD is a life-threatening complication of stem cell transplants, including allogeneic hematopoietic stem cell transplants. In these cases, the donor’s, or gra...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters